SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation.

ABSTRACT: The expression of SEL1L (suppressor/enhancer of Lin-12-like) is found to be downregulated in clinical breast cancer (BRC) and lymph node metastasis tissues, as well as in carboplatin-resistant BRC cell lines. In this study, reduced SEL1L expression was linked to poor prognosis in BRC, while silencing SEL1L in BRC cells led to increased epithelial-mesenchymal transition (EMT) and metastasis. Furthermore, SEL1L sensitized cancer cells to the anti-cancer drug carboplatin, leading to enhanced apoptosis in both in vivo and in vitro settings. Mechanistically, SEL1L suppressed the expression of oncogenic Shh protein by promoting its ubiquitination-proteasomal degradation, thereby inhibiting EMT and improving cellular sensitivity to carboplatin in BRC cells via hedgehog signaling pat

SUBMITTER: Zhou H 

PROVIDER: S-EPMC12648483 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature